161 results on '"Kollia, Georgia"'
Search Results
2. A Generalization of the Weibull Distribution with Application to the Analysis of Survival Data
3. Apoptosis in Endometriosis
4. Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
5. BMS-986158, a Small Molecule Inhibitor of the Bromodomain and Extraterminal Domain Proteins, in Patients with Selected Advanced Solid Tumors: Results from a Phase 1/2a Trial
6. Abstract CT022: CheckMate 848: A randomized, open-label, phase 2 study of nivolumab in combination with ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden
7. A Graphical Procedure for Comparing Goodness-of-Fit Tests
8. The effects of liver impairment on the pharmacokinetics of brivanib, a dual inhibitor of fibroblast growth factor receptor and vascular endothelial growth factor receptor tyrosine kinases
9. Lack of food effect on single-dose pharmacokinetics of brivanib, and safety and efficacy following multiple doses in subjects with advanced or metastatic solid tumors
10. Pharmacokinetics and Tolerability of Intramuscular, Oral and Intravenous Aripiprazole in Healthy Subjects and in Patients with Schizophrenia
11. Two sets of isotones for comparing tests of exponentiality
12. Estimation Using Quantile Function Structure with Emphasis on Weibull Distribution
13. Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
14. Lack of Effect of Brivanib on the Pharmacokinetics of Midazolam, a CYP3A4 Substrate, Administered Intravenously and Orally in Healthy Participants
15. 393 First-in-human phase 1/2a study of the novel nonfucosylated anti–CTLA-4 monoclonal antibody BMS-986218 ± nivolumab in advanced solid tumors: initial phase 1 results
16. Anti-CTLA-4 probody BMS-986249 alone or in combination with nivolumab in patients with advanced cancers: Initial phase I results.
17. In Vivo Evaluation of the Absorption and Gastrointestinal Transit of Avitriptan in Fed and Fasted Subjects Using Gamma Scintigraphy
18. Benefits and disadvantages of joint hypermobility among musicians
19. Pharmacokinetics and Tolerability of Buspirone during Oral Administration to Children and Adolescents with Anxiety Disorder and Normal Healthy Adults
20. Pharmacodynamics and Pharmacokinetics of Omapatrilat in Heart Failure
21. The Pharmacokinetics and Pharmacodynamics of Irbesartan in Heart Failure
22. CA224-060: A randomized, open label, phase II trial of relatlimab (anti-LAG-3) and nivolumab with chemotherapy versus nivolumab with chemotherapy as first-line treatment in patients with gastric or gastroesophageal junction adenocarcinoma.
23. Single-dose safety and pharmacokinetics of oral gatifloxacin in subjects with hepatic impairment.: 80E.
24. Effect of a high-fat meal on the bioavailability of gatifloxacin in healthy volunteers.: 79E.
25. A pharmacokinetic interaction study of avitriptan and propranolol
26. The Effects of Age and Gender on the Single Dose Pharmacokinetics of Avitriptan Administered to Healthy Volunteers
27. A phase I study of AL101, a pan-NOTCH inhibitor, in patients (pts) with locally advanced or metastatic solid tumors.
28. Nature and Impact of Musculoskeletal Problems in a Population of Musicians
29. Additional file 1: Figure S1. of Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy
30. Additional file 2: Table S1. of Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy
31. Additional file 4: Figure S2. of Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy
32. Additional file 5: Figure S3. of Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy
33. Additional file 6: Figure S4. of Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy
34. Additional file 3: Table S2. of Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy
35. Bilateral transient osteoporosis of the hip in pregnancy
36. Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy
37. Nivolumab dose selection: challenges, opportunities and lessons learned for cancer immunotherapy
38. Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab
39. Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer
40. Long-term survival of ipilimumab-naive patients (pts) with advanced melanoma (MEL) treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) in a phase I trial.
41. A phase I dose escalation and cohort expansion study of lirilumab (anti-KIR; BMS-986015) in combination with nivolumab (anti-PD-1; BMS-936558, ONO-4538) in advanced solid tumors.
42. Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients (pts) with advanced non-small-cell lung cancer (NSCLC): Survival and clinical activity by subgroup analysis.
43. Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
44. Survival and long-term follow-up of safety and response in patients (pts) with advanced melanoma (MEL) in a phase I trial of nivolumab (anti-PD-1; BMS-936558; ONO-4538).
45. Survival, safety, and response duration results of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in a phase I trial in patients with previously treated metastatic renal cell carcinoma (mRCC): Long-term patient follow-up.
46. Nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients with advanced solid tumors: Survival and long-term safety in a phase I trial.
47. Survival and long-term follow-up of the phase I trial of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in patients (pts) with previously treated advanced non-small cell lung cancer (NSCLC).
48. Association of tumor PD-L1 expression and immune biomarkers with clinical activity in patients (pts) with advanced solid tumors treated with nivolumab (anti-PD-1; BMS-936558; ONO-4538).
49. Clinical activity and safety of antiprogrammed death-1 (PD-1) (BMS-936558/MDX-1106/ONO-4538) in patients (pts) with previously treated, metastatic renal cell carcinoma (mRCC): An updated analysis.
50. Anti-PD-1 (BMS-936558, MDX-1106) in patients with advanced solid tumors: Clinical activity, safety, and a potential biomarker for response.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.